PharmaBlock Sciences (Nanjing), Inc.
SZSE:300725.SZ
39.57 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,688.62 | 1,725.204 | 1,594.7 | 1,201.629 | 1,022.229 | 662.231 | 478.254 | 273.251 | 188.378 | 136.131 | 76.639 | 58.547 |
| Cost of Revenue
| 1,046.01 | 991.669 | 869.498 | 623.343 | 554.169 | 320.574 | 201.744 | 103.513 | 63.367 | 52.91 | 25.485 | 17.61 |
| Gross Profit
| 642.61 | 733.535 | 725.202 | 578.286 | 468.06 | 341.657 | 276.51 | 169.738 | 125.011 | 83.221 | 51.154 | 40.937 |
| Gross Profit Ratio
| 0.381 | 0.425 | 0.455 | 0.481 | 0.458 | 0.516 | 0.578 | 0.621 | 0.664 | 0.611 | 0.667 | 0.699 |
| Reseach & Development Expenses
| 107.33 | 169.174 | 168.324 | 114.024 | 90.927 | 69.221 | 44.35 | 24.732 | 16.307 | 8.987 | 7.448 | 6.958 |
| General & Administrative Expenses
| 50.937 | 65.017 | 71.935 | 66.559 | 66.986 | 25.579 | 16.459 | 14.372 | 28.388 | 28.405 | 3.898 | 2.452 |
| Selling & Marketing Expenses
| 9.895 | 53.207 | 40.956 | 24.285 | 30.662 | 24.254 | 20.678 | 17.644 | 11.717 | 4.466 | 2.611 | 1.945 |
| SG&A
| 60.832 | 118.224 | 112.891 | 90.843 | 97.647 | 49.833 | 37.137 | 32.017 | 40.105 | 32.872 | 6.508 | 4.397 |
| Other Expenses
| 223.243 | 261.537 | 147.483 | 92.068 | 60.548 | 55.744 | 11.429 | 2.938 | 3.935 | 2.76 | 1.819 | 1.026 |
| Operating Expenses
| 391.405 | 522.596 | 428.698 | 296.935 | 249.123 | 174.798 | 132.311 | 88.906 | 84.022 | 60.717 | 25.808 | 19.998 |
| Operating Income
| 251.205 | 184.6 | 296.706 | 492.956 | 194.127 | 163.536 | 142.977 | 74.122 | 40.774 | 24.135 | 24.646 | 20.557 |
| Operating Income Ratio
| 0.149 | 0.107 | 0.186 | 0.41 | 0.19 | 0.247 | 0.299 | 0.271 | 0.216 | 0.177 | 0.322 | 0.351 |
| Total Other Income Expenses Net
| -2.309 | 36.775 | 26.558 | 14.813 | 10.378 | 8.815 | 11.429 | 2.938 | 3.879 | 2.76 | 1.708 | 1.026 |
| Income Before Tax
| 248.896 | 221.375 | 323.263 | 507.769 | 204.505 | 172.351 | 154.406 | 77.06 | 44.653 | 26.896 | 26.353 | 21.583 |
| Income Before Tax Ratio
| 0.147 | 0.128 | 0.203 | 0.423 | 0.2 | 0.26 | 0.323 | 0.282 | 0.237 | 0.198 | 0.344 | 0.369 |
| Income Tax Expense
| 29.356 | 24.014 | -2.627 | 4.003 | 20.3 | 20.279 | 19.907 | 9.272 | 9.609 | 7.038 | 3.896 | 3.336 |
| Net Income
| 219.54 | 197.361 | 314.224 | 486.559 | 184.208 | 152.069 | 133.363 | 67.179 | 36.115 | 19.934 | 22.471 | 18.247 |
| Net Income Ratio
| 0.13 | 0.114 | 0.197 | 0.405 | 0.18 | 0.23 | 0.279 | 0.246 | 0.192 | 0.146 | 0.293 | 0.312 |
| EPS
| 1.1 | 0.99 | 1.57 | 2.45 | 0.99 | 0.82 | 0.72 | 0.47 | 0.27 | 0.18 | 0.53 | 0.17 |
| EPS Diluted
| 1.1 | 0.98 | 1.57 | 2.44 | 0.75 | 0.82 | 0.72 | 0.47 | 0.27 | 0.18 | 0.53 | 0.17 |
| EBITDA
| 443.021 | 403.557 | 471.528 | 581.731 | 229.61 | 196.731 | 180.957 | 89.442 | 53.429 | 26.528 | 30.206 | 25.146 |
| EBITDA Ratio
| 0.262 | 0.234 | 0.296 | 0.484 | 0.225 | 0.297 | 0.378 | 0.327 | 0.284 | 0.195 | 0.394 | 0.429 |